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Electrochemical analysis of sweat using soft bioelectronics on human skin provides a new route for noninvasive
glucose monitoring without painful blood collection. However, sweat-based glucose sensing still faces many
challenges, such as difficulty in sweat collection, activity variation of glucose oxidase due to lactic acid secretion
and ambient temperature changes, and delamination of the enzyme when exposed to mechanical friction and
skin deformation. Precise point-of-care therapy in response to the measured glucose levels is still very
challenging. We present a wearable/disposable sweat-based glucose monitoring device integrated with a
feedback transdermal drug delivery module. Careful multilayer patch design and miniaturization of sensors
increase the efficiency of the sweat collection and sensing process. Multimodal glucose sensing, as well as
its real-time correction based on pH, temperature, and humidity measurements, maximizes the accuracy of
the sensing. The minimal layout design of the same sensors also enables a strip-type disposable device. Drugs
for the feedback transdermal therapy are loaded on two different temperature-responsive phase change nano-
particles. These nanoparticles are embedded in hyaluronic acid hydrogel microneedles, which are additionally
coated with phase change materials. This enables multistage, spatially patterned, and precisely controlled drug
release in response to the patient’s glucose level. The system provides a novel closed-loop solution for the





Diabetes is one of the most prevalent chronic diseases, causing un-
controllable blood glucose levels (1). Patients with diabetes are ad-
vised to check their blood glucose level daily and to take periodic
insulin shots for continuous management of their blood glucose level
(2). However, patients often do not follow this recommendation be-
cause of the pain and accompanying intense stress of repetitive blood
collection and insulin shots. This often leads to various severe diabetic
complications, such as cardiovascular and kidney diseases, stroke, blind-
ness, and nerve degeneration. In addition, insulin overtreatment causes
an abrupt drop in the blood glucose concentration, which may cause
seizures, unconsciousness, and even death. Therefore, a novel method
for painless and stress-free glucose monitoring (3–5) and precise main-
tenance of homeostasis through controlled drug delivery (6, 7) is highly
desirable.
Extensive efforts have been made to develop noninvasive sweat-
based biomarker monitoring methods. Wearable biosensors enable
continuous monitoring of metabolites [including glucose (3–5), lac-
tate (8), and alcohol (9)] and electrolytes [including potassium (3),
calcium (10), and heavy metal ions (11)] in sweat. The estimation
of the blood glucose concentration based on the sweat-based glu-
cose measurement is a potential solution (12, 13). However, many
challenges still exist for the accurate sweat-based glucose measure-
ment (14, 15). For example, the sweat collection procedure is tedious,
and the sweat collection times vary depending on environmentalconditions. In addition to the difficulty of measuring glucose levels
in sweat because of its much smaller concentration than that in blood,
lactic acid in sweat, ambient temperature changes, and various med-
ications can induce errors in enzyme-based glucose sensing. Me-
chanical friction and deformation of devices on soft human skin can
delaminate the enzyme from the glucose sensor and cause mechanical
fractures in devices. A closed-loop system with the feedback delivery
of a precisely controlled amount of drugs in response to the glucose
monitoring result is another important unaccomplished goal for main-
taining homeostasis (6, 7).
Various kinds of flexible and stretchable devices based on an
ultrathin (16–18) and stretchable design (19, 20) have been devel-
oped for monitoring individual health status and delivering the corre-
sponding feedback therapy (21, 22). Here, we develop a patch-based
wearable/strip-type disposable system for noninvasive sweat glucose
monitoring and microneedle-based point-of-care therapy (23). Key nov-
el advantages of this system include (i) mass production–compatible
porous metal-based electrodes and fabrication processes, (ii) miniatur-
ized sensor design that allows for reliable sweat analysis even with an
infinitesimal amount of sweat, (iii) patch- and disposable-type design
for enhancing practical applicability, (iv) multiple sweat control and
uptake layers for efficient sweat collection, (v) a porous gold nanos-
tructure for maximizing the electrochemically active surface area for
detection of a small amount of glucose in sweat with high sensitivity,
(vi) multiple glucose sensing devices for enhanced accuracy, and (vii)
multistage and precisely controlled transdermal drug [metformin or
chlorpropamide (type 2 diabetes drugs)] delivery through biocompatible
hyaluronic acid hydrogel microneedles containing drug-loaded phase
change nanoparticles (PCNs). Metformin is one of the first-line drugs
for treating type 2 diabetes (24). Because drug delivery through the
skin can bypass the digestive system, transdermal delivery of metfor-
min requires a lower dosage of drugs than oral delivery and prevents1 of 8
SC I ENCE ADVANCES | R E S EARCH ART I C L Egastrointestinal side effects (23). This novel system for high-fidelity
sweat glucose measurement and feedback-controlled drug delivery
enables efficient management of blood glucose concentration without
pain and stress.RESULTS
System design of the wearable diabetes patch and
disposable strip
The patch-based wearable devices in Fig. 1A have an ultrathin and
stretchable design (fig. S1A), which enables conformal contact with
the skin for efficient sweat collection and high performance under
physical deformation. The same sensors can be further miniatur-
ized and fabricated as a disposable strip (Fig. 1B). Depending onLee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017the sweat glucose concentration, an appropriate amount of metfor-
min (or chlorpropamide) is transdermally delivered through micro-
needles. The drug delivery can be thermally controlled in a multistage
manner. The microneedles assembled on the multichannel thermal
actuator can be periodically replaced with new ones (Fig. 1C and
fig. S1, B and C). These patch-type devices are fabricated on a handle
substrate and then transfer-printed onto a thin silicone patch (fig. S2).
The strip-type sensor is fabricated on a thin polyimide (PI) substrate.
Patterned electrochemical functionalization completes the fabrication.
The system operation sequence is schematically described in fig. S3.
After wearing the patch, sweat accumulates in the porous sweat-uptake
layer. A waterproof band behind the silicone patch aids in sweat collec-
tion and prevents delamination of the patch from the skin. A porous
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Fig. 1. Wearable/disposable sweat monitoring device and microneedle-based transdermal drug delivery module. (A) Optical camera image (top; dotted line,
edges of the patch) and schematic (bottom) of the wearable sweat monitoring patch. A porous sweat-uptake layer is placed on a Nafion layer and sensors. (B) Optical
camera image (top) and schematic (bottom) of the disposable sweat monitoring strip. (C) Optical camera image (top; dotted line, edges of the patch) and schematic
(bottom) of the transdermal drug delivery device. Replacement-type microneedles are assembled on a three-channel thermal actuator. (D) Schematic drawing of the
glucose sensor in an exploded view. PB, prussian blue. (E) Minimum volume of the artificial sweat required for sensing with different sizes of the glucose sensor. (F)
Scanning electron microscope (SEM) images before (left) and after (right) immobilization of the enzyme (enz.) on the porous gold electrode. (G) Comparison of the H2O2
sensitivity in the planar and porous gold electrode deposited with Prussian blue at different H2O2 concentrations. (H) Schematic of the drug-loaded microneedles. The
right inset describes details of different PCNs. (I) SEM image of the microneedles. (J) Confocal microscope images of the released dye from microneedles (MN) (top
view) into the 4% agarose gel (green, agar; red, dye). (K) Infrared (IR) camera image of the three-channel (ch) thermal actuator.2 of 8









sweat-uptake layer helps in the immobilization of the enzyme (25) and
screens out negatively charged molecules that may affect the glucose
sensing (for example, drug molecules contained in sweat, such as ac-
etaminophen or acetylsalicylic acid) (25, 26). A humidity sensor moni-
tors the critical amount of sweat for reliable glucose sensing by
measuring impedance change by sweat generation. Above the critical
humidity, the glucose, pH, and temperature sensors begin taking mea-
surements to determine correlated blood glucose level. The pH and
temperature sensors correct potential errors of the enzyme-based glu-
cose level measurement in real time. Upon hyperglycemia, thermal
actuation controls the feedback transdermal delivery of metformin
loaded in PCNs.
Materials and key device design
A series of stretchable sensors (humidity, glucose, pH, and tempera-
ture) are monolithically integrated (Fig. 1A) for efficient sweat-based
glucose sensing. Multipoint sensing for glucose (triple) and pH (quad-
ruple) improves the detection accuracy (fig. S1A). In the glucose and
pH sensors, the reference and counter electrodes are designed to be
packed as closely as possible to minimize the required amount of sweat
(Fig. 1D). As the working electrode diameter (Dwork) decreases, the re-
quired sweat amount can be reduced to as small as 1 ml (Fig. 1E), which
is a 20-fold decrease from that previously reported by Lee et al. (5). The
working electrode consists of porous gold formed by electrodeposition
and enzymes [glucose oxidase (GOx)] drop-casted on it and then
covered by Nafion and sequentially cross-linked by glutaraldehyde
(Fig. 1F). The porous structure allows for a larger electrochemically ac-
tive surface area (27, 28) and stronger enzyme immobilization (29, 30).
Cyclic voltammograms (fig. S4A) and ac impedance measurements
(fig. S4, B and C) using the Fe(CN)6
3−/4− redox couple show a high
charge storage capacity and low interfacial impedance in the porous
structure. The high H2O2 reducing catalytic activity of the porous
structure (Fig. 1G and fig. S4D) confirms the enhanced sensitivity.
Robustly cross-linked enzymes on the porous metal structure also
enhance the reliability of the sensor under mechanical friction and
deformation.
Film-type microneedles (fig. S1B) are integrated on top of the
stretchable heater (fig. S1C), and these needles can be periodically re-
placed (Fig. 1C). For the multistep and precisely controlled drug deliv-
ery, two types of metformin-loaded PCNs [PCN1, melting transition
temperature (Tm,1) = 38°C; PCN2, Tm,2 = 43°C] are embedded in the
hyaluronic acid hydrogel microneedles (Fig. 1H). The hyaluronic acid
hydrogel is a widely used biocompatible material (31). An additional
coating with phase change materials (PCMs) prevents unwanted disso-
lution of the hyaluronic acid matrix in contact with interstitial fluids
(Fig. 1H). Controlled thermal actuation by the integrated heater acti-
vates either PCN1 alone or both PCNs (fig. S5). An SEM image of
the fabricated microneedles is shown in Fig. 1I. Confocal microscope
images show the dye release from microneedles into 4% agarose gel
(tissue-like gel) (Fig. 1J) (32). The heater is designedwith three channels
(Fig. 1K) and triggers the multistage drug delivery that can be tuned
with thermal patterns.
Sweat control optimization
Efficient use of the generated sweat is an important issue in the sweat-
based monitoring system, which is enabled by the sweat-uptake and
waterproof layers. A porous and hydrophilic sweat-uptake layer (Fig. 2A,
inset) (33, 34), which is placed on the Nafion layer and sensors, absorbs
sweat and delivers it to the sensors through the Nafion layer (fig. S6A).Lee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017Thewaterproof band added on the elastomeric silicone patch covers the
outside to separate the sweat from external humidity (Fig. 2A), sup-
presses sweat evaporation (fig. S6B), and prevents delamination of the
patch during skin deformation (Fig. 2B). The strip-type sensor absorbs
sweat by the capillary force formed by the gap (fluidic channel) between
the sweat-drawing layer and substrate (Figs. 1B, bottom inset, and 2C).
The miniaturized sensor design (Fig. 1, D and E) and the fast collection
of sweat enable rapid sensing. The miniaturized glucose sensor can be
stably operated with only 1 ml of sweat (Fig. 2D and fig. S6, C and D).
Electrochemical and electrical characterization of
individual sensors
The humidity sensor monitors the sweat collection procedure through
impedance changes of poly(3,4-ethylenedioxythiophene) (PEDOT) in-
terdigitated electrodes to estimate an appropriate starting point of sweat
analysis (Fig. 2E). The glucose sensor based on a Prussian blue–
deposited porous gold electrode is calibrated to the glucose concentra-
tion range between 10 mMand 1mM (typical glucose concentrations in
human sweat) by the galvanostatic method (Fig. 2F and fig. S7, A and
B). These glucose concentrations correspond to typical sweat glucose
concentrations of both hypoglycemic and hyperglycemic patients as
well as healthy people (12, 13). The glucose sensor is stable under
mechanical deformation (fig. S7C) and selectively detects glucose in
the presence of other biomolecules [including ascorbic acid, uric acid,
and lactic acid (3, 35)] and drugs [including acetaminophen, acetylsa-
licylic acid, andmetformin (fig. S7D) (36–38)], whose concentrations
are in values commonly found in the human sweat. The glucose sensor
works for one full day without additional calibration under ambient
conditions and for several days depending on storage conditions
(fig. S7E).
The enzyme-based glucose sensor shows deviations at different pH
levels (fig. S7F), and thus simultaneous monitoring of pH levels is im-
portant. The pH sensor measures changes in the open circuit potential
(OCP) between a polyaniline (PANi)–deposited working electrode and
an Ag/AgCl electrode. The pH sensor is calibrated using standard pH
buffer solutions (Fig. 2G and fig. S8A) and maintains stable operation
under deformation (fig. S8B). Because the dependence of measured
OCP and the pH was not linear, the calibration curves were obtained
for every pH difference of 0.5. The pH sensor is reliable over repeated
use at different pH levels (fig. S8C) and different temperatures (fig. S8D).
The resistor-based temperature sensor is also calibrated for skin tempera-
ture monitoring (Fig. 2H). The simultaneous use of these co-integrated
sensors can enhance the accuracy of glucose sensing. For example,
metabolic secretion of lactic acid in sweat lowers the pH level to 4 to 5.
The simultaneous pH sensing can correct this pH-dependent devia-
tion (Fig. 2I and fig. S7F) of the enzyme-based glucose sensor. Simulated
hyperglycemia—0.3mMsweat glucose—ismonitored in vitro under two
different pH variation settings (5→4→5 and 5→6→5; Fig. 2J, left and
right). In both cases, real-time correction increases glucose measurement
accuracy. The glucose sensor with the current device setting does not
show significant deviations at different temperatures (Fig. 2K).
Thermoresponsive PCNs
PCMs have melting temperatures that are low but above human body
temperature, and thus they are widely used in the thermoresponsive
drug delivery (39). PCNs are made of PCMs, drugs, and biocompatible
ligands (Fig. 3A). Different PCNs enable temperature-dependent
stepwise drug delivery. We use palm oil (PCN1, Tm = 38°C) and tride-
canoic acid (PCN2, Tm = 43°C), whichmelt above the skin temperature3 of 8
SC I ENCE ADVANCES | R E S EARCH ART I C L E
D
ow
nloa(30°C; fig. S9A). The drugs (metformin or chlorpropamide) are em-
bedded in the PCM matrix (Fig. 3A and fig. S9, B to D). Pluronic F-
127 and3,4-dihydroxyl-L-phenylalanine (DOPA)–conjugatedhyaluronic
acid (fig. S10, A and B) are used as ligands, which make an oil-in-water
emulsion (fig. S11A). Cryogenic transmission electronmicroscopy (cryo-
TEM) images show that PCNs below the melting temperature are solid
(Fig. 3, B and C, left). Above the melting temperature, PCNs change to
liquid and aggregate (Fig. 3, B and C, right). Cytotoxicity tests show that
both PCNs are nontoxic and suitable for biomedical applications
(fig. S11B). The hydrodynamic diameters and negative zeta potentials
of the PCNs slightly increase and decrease, respectively, as the tempera-
ture increases from the skin temperature (30°C; fig. S9A) to above
melting temperatures (40° and 45°C; Fig. 3D and fig. S11C). The
PCM matrices can block the drug release before thermal actuation.
Their stepwise temperature-dependent melting controls the amount
of the drug release.When the temperature reaches 40°C, only the drugs
contained in PCN1 are released, whereas at 45°C, the drugs in both
PCN1 and PCN2 are released (fig. S11D).Lee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017Microneedle fabrication and multistage drug delivery
The microneedles are fabricated by molding the hyaluronic acid hy-
drogel matrix containing drug-loaded PCNs, followed by an additional
PCM spray coating (Fig. 3E, left, and fig. S12). A confocal laser fluo-
rescence microscope image shows that the dye-loaded PCNs are well
embedded in the microneedles (Fig. 3E, right). Hydrogel-based micro-
needles dissolve when they come in contact with body fluids (Fig. 3F,
left), whereas the PCM coating prevents the dissolution before the
controlled melting of the PCM (Fig. 3F, right). The microneedles
should be stiff enough to penetrate into the skin (40); compression
tests confirm their mechanical strength (Fig. 3G). The microneedles
successfully penetrate into 4% agarose gel (tissue-like gel) and generate
pores (Fig. 3H, left). After poration by microneedles, vertical heat
transfer dissolves the outside PCM coating and embedded PCNs. Al-
though accidental peel-offs create small defects in the PCM coating,
the drug contained in the PCNs is not released. The vertical tempera-
ture distribution of the agarose gel imaged by an IR camera confirms




























































































































































































Fig. 2. Optimization of the sweat control and characterization of individual sensors. (A) Optical image of the wearable sweat analysis patch with a sweat-uptake
layer and a waterproof band. The inset shows the magnified view of the porous sweat-uptake layer. (B) Optical image of the sweat analysis patch under deformation.
(C) Optical image of the disposable sweat analysis strip on human skin with perspiration. (D) Glucose (glu.) concentration measurement at different sweat volumes (0.3 mM
glucose in artificial sweat). (E) Optical image (top) and calibration curve (bottom) of the humidity sensor. Inset shows the image before and after wetting of the sensor.
(F) Optical image (top) and calibration curve (bottom) of the glucose sensor. (G) Optical image (top) and calibration curve (bottom) of the pH sensor. (H) Optical image (top)
and calibration curve (bottom) of the temperature sensor. (I) Changes of the relative sensitivity of the uncorrected glucose sensor at different pH levels. The relative sensitivity
(S/So) is defined as measured sensitivity divided by sensitivity at pH 5. (J) In vitro monitoring of glucose changes with (green) and without (red) correction using simultaneous
pH measurements (blue). (K) Calibration curves of the glucose sensor at different temperatures.4 of 8






drug release, we heated themicroneedles containing dyes from 25° to
45°C (Fig. 3I). There is a negligible release under and around the skin
temperature (30°C) due to the PCMcoating and PCNs.At the elevated
temperature (40°C), the PCM coating onmicroneedles and PCN1 are
dissolved, andmetformin in PCN1 is released. At the higher tempera-
ture (45°C), metformin in both PCN1 and PCN2 is released. Spatial
patterning of the embedded heater subdivides the release steps fur-
ther, which is precisely controlled (fig. S13A) by co-integrated tem-
perature sensors (fig. S13, B and C). Heaters consisting of the three
channels together with the two types of PCNs result in eight different
spatiothermal patterns (Fig. 3J) and six-stage programmeddye-release
profiles (Fig. 3K).
Sweat-based glucose monitoring on human subjects
Wearable/disposable sweat-based glucose sensors are used for human
sweat analysis. The wearable patch is connected to a portable electro-
chemical analyzer (Fig. 4A and fig. S14). Themonitoring starts with hu-
midity sensing to determine the optimum point to start sweat analysis
(Fig. 4B). When the sweat-uptake layer absorbs a sufficient amount of
sweat, the glucose and pH sensors detect the sweat glucose and pH
levels, respectively. The triple glucose and quadruple pH sensing (fig.
S1A) improve the detection accuracy (Fig. 4C). The correction using
the measured pH enables more accurate glucose sensing (Fig. 4D).
The patch works reliably under different skin temperatures (tempera-
ture range, 30° to 37°C) before, during, and after physical movements
(fig. S15, A and B). The changes of skin temperature with the current
experimental setting are small because of homeostatic functions of the
nervous system (41). The patch is reusable and/or reattachable multiple
times (fig. S15, C and D).Lee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017The disposable strip-type sensor is more convenient for the sweat
analysis. The strip-type sensor first absorbs sweat (Fig. 2C) because of
the capillary effect, and it is then connected to the hardware for sweat
analysis through a ZIF connector (Fig. 4E). The absorbed sweat should
cover the surface of both pH and glucose sensors (Fig. 4F). The amount
of absorbed sweat can be monitored by measuring the impedance be-
tween the electrodes of the glucose sensor (Pt counter electrode and
Ag/AgCl reference electrode) and those of the pH sensor (two PANi-
deposited working electrodes) (Fig. 4G). The strip-type sensor can be sta-
bly operated with 4 ml of sweat (fig. S16A). When the sweat covers both
glucose and pH sensors, the measurements begin (Fig. 4H). The calibra-
tion curves for a strip-type device are shown in fig. S16 (B and C).
The sweat pH levels vary among subjects and depending on the phys-
iological conditions of each subject (fig. S17A). The sweat glucose levels
corrected by pH measurements before and after a meal agree well with
the sweat glucose levels measured among subjects using a commercial
glucose assay kit (Fig. 4I). Statistical analysis confirms the reliable corre-
lation of sweat glucose levels measured by the wearable and disposable
sweat glucose sensors with the blood glucose levels measured by a com-
mercial glucosemeter (fig. S17B). For the accurate estimationof the blood
glucose level based on the sweat glucose level, the correlation factor be-
tween the glucose concentration of blood and sweat should be found for
each individual subject with enough data (fig. S17C). With this data, it is
clear that blood glucose concentration tends to vary before and after a
meal, similarly to the measured sweat glucose concentration (Fig. 4J).
Controlled transdermal drug delivery using microneedles
Transdermal drug delivery experiments based on the fabricated micro-
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Fig. 3. Characterization of PCNs and PCN-loaded microneedles. (A) Schematic illustration of the PCN. HA, hyaluronic acid. (B) Cryo-TEM image of PCN1 (palm oil)
below the melting temperature (left) and TEM image of PCN1 above the melting temperature (right). (C) Cryo-TEM image of PCN2 (tridecanoic acid) below the melting
temperature (left) and TEM image of PCN2 above the melting temperature (right). (D) Dynamic light scattering size measurement of PCNs at 30° (skin temperature), 40°,
and 45°C. (E) Optical image (left) and confocal fluorescence (FL) microscope image (right) of PCM-coated microneedles. Microneedles contain dye-loaded PCNs for
imaging. (F) Microneedle dissolution test in PBS before (left) and after (right) the PCM coating. (G) Mechanical strength test of microneedles in their dry and wet states.
(H) Confocal microscope image of microneedles penetrating into 4% agarose gel (left) and IR camera image of the thermal actuation on the gel (right). (I) Drug-release
profile from microneedles. (J) IR camera images of eight different spatiothermal profiles using the three-channel thermal actuator for multistage drug delivery. (K) Multistage
drug-release profile. a.u., arbitrary units.5 of 8









diabetic (db/db) mice (type 2 diabetes mellitus model). The in vivo
treatment starts with lamination of a therapeutic patch on the shaved
abdomen of the db/db mouse (Fig. 4K). Trypan blue staining on the
mouse skin confirms that the microneedles can successfully penetrate
the skin for the drug (metformin) delivery (fig. S18A). The integrated
heaters modulate the amount of the drug delivery by the controlled
thermal actuation (fig. S18B). Control groups that have no patch (black),
microneedles without diabetes drugs (red), andmicroneedles with diabe-
tes drugs (blue, dose 1; green, dose 2) are used (Fig. 4L). The experimental
groups (blue and green) show significant decrease in blood glucose level
compared to the control groups (black and red). As more metformin is
delivered to the db/db mice, the blood glucose level is suppressed more.
The blood glucose concentration of the measurement group (dose 2,
green) decreased to 7.6 mM, which is a normoglycemic state (<11 mM).DISCUSSION
We report a novelmaterial structure, device design, and system integra-
tion strategy for a sweat glucose monitoring device integrated with
feedback transdermal drug delivery microneedles. Depending on the
design, the device can be either wearable-patch type or disposable-strip
type. For efficient sweat control and sensing, the sweat monitoring
patch is assembled with multiple sweat-uptake and waterproof layers,
and sensor sizes are miniaturized to the point that ~1 ml of sweat is suf-
ficient for reliable measurement. The measurements of sweat glucose
levels with real-time correction based on pH, temperature, and humid-Lee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017ity sensing are accurate under various environment changes. The sweat
glucose data arewell correlatedwith the blood glucose levels. For precise
and timely drug delivery, two types of metformin-loaded PCNs are em-
bedded in the PCM-coated microneedles. The thermoresponsive mi-
croneedles controlled by multichannel heaters enable the multistage
and spatially patterned transdermal drug release in response to the
measured sweat glucose level.
For practical application of the current system, there are several
things to improve. The long-term stability and uniformity of sensors
are particularly important to make the system practically applicable
to human subjects with minimum recalibrations. Further studies about
the correlation between glucose levels of blood and sweat are needed
before application to diabetic patients. Although metformin used in
the system shows slow suppression of the blood glucose levels due to
its working mechanism (42), another kind of drug (for example, chlor-
propamide) can be loaded for synergistic treatment or fast regulation of
blood glucose level. With further improvements in these points, clinical
translation can be pursued for sweat-based sensing and feedback ther-
apy. The current system provides important new advances toward the
painless and stress-free point-of-care treatment of diabetes mellitus.MATERIALS AND METHODS
Fabrication process of the device array
The wearable device fabrication began with spin-coating of the PI pre-
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Fig. 4. Sweat-based glucose monitoring and feedback therapy in vivo. (A) Optical camera image of the subject using a cycle ergometer for sweat generation with
the wearable patch on the subject’s arm. (B) Real-time humidity monitoring to check the accumulation of sweat. (C) Multimodal glucose and pH sensing to improve
detection accuracy. (D) Measured sweat glucose concentrations (n = 3), pH levels (n = 4), and corrected sweat glucose level (n = 3) based on the averaged pH (dotted
line, glucose concentration measured by a commercial glucose assay). (E) Optical camera image of the disposable strip-type sensors connected to a zero insertion force
(ZIF) connector. (F) Optical camera images of the sweat uptake via the fluidic channel of the strip. (G) Humidity monitoring of the disposable strip using impedance
measurements. (H) Sweat glucose and pH monitoring using the disposable strip. (I) Ratio of sweat glucose concentrations (n = 3) measured by the patch and a
commercial glucose assay with and without the pH-based correction before and after a meal. (J) Comparison of the sweat and blood glucose concentrations before
and after a meal. (K) Optical camera image of the transdermal drug delivery device on the db/db mouse. (L) Blood glucose levels of the db/db mice for the treated
groups (microneedles with the drugs) and control groups (without the patch, microneedle without the drugs) (*P < 0.05, **P < 0.01 versus control, Student’s t test).6 of 8









followed by thermal curing of the PI. ACr/Au thin film (~30 nm/~70 nm)
was deposited on electrodes by thermal evaporation. The Cr/Au thin film
was patterned by photolithography and wet etching. A Cr/Pt thin film
(~10 nm/~100 nm) was deposited by sputtering and patterned by pho-
tolithography for the temperature sensor and the counter electrode of
the glucose sensor. The top epoxy layer (~1.5 mm; SU8-2, MicroChem)
was coated and patterned by photolithography. The bottom PI layer
was selectively isolated by photolithography and reactive-ion etching.
The device was transfer-printed onto a polydimethylsiloxane (PDMS)
substrate (Sylgard 184, Dow Chemical) using a water-soluble tape
(product #5414, 3M). The strip-type devicewas fabricated on the PI film
(125 mm; Isoflex) using the same procedures.
Functionalization of sensors and electrodes with
electrochemically active materials
(i) PEDOT electrodeposition. A solution of 0.01 M 3,4-ethylenediox-
ythiophene (product #483028, Sigma-Aldrich) and0.1MLiClO4 (product
#271004, Sigma-Aldrich) in acetonitrile (product #271004, Sigma-
Aldrich) was prepared. The gold electrode was dipped in the solution,
and galvanostatic electrodeposition was performed for 40 s at 1.2 V
(potential versus commercial Ag/AgCl electrode).
(ii) Ag/AgCl electrodeposition. An aqueous solution of 5 mM
AgNO3 (product #209139, Sigma-Aldrich) and 1 M KNO3 (product
#P8394, Sigma-Aldrich) was prepared. The gold electrode was dipped
in the prepared solution. The potential was swept from −0.9 to 0.9 V
versus a Ag electrode for 14 segments at a scan rate of 0.1 V s−1. For
chlorination, the electrode was dipped in an aqueous solution of 0.1 M
KCl (product #P5405, Sigma-Aldrich) and 0.01MHCl (product #H1758,
Sigma-Aldrich). The potential was swept from −0.15 to 1.05 V versus a
commercial Ag/AgCl electrode for four segments at a scan rate of
0.05 V s−1.
(iii) Porous gold electrodeposition. An aqueous solution of 2 mM
HAuCl4 (product #70-0500, Strem Chemicals) in 2 MH2SO4 (product
#320501, Sigma-Aldrich) was prepared. The gold electrode was dipped
in the prepared solution. The porous gold was electrodeposited by the
galvanostatic method for 5 min at −1 V with a Pt counter electrode and
a commercial Ag/AgCl electrode (total charge, ~0.5 C).
(iv) Prussian blue electrodeposition. An aqueous solution of 10 mM
KCl, 2.5 mM K3[Fe(CN)6] (product #P702587, Sigma-Aldrich), and
2.5 mM FeCl3·6H2O (product #236489, Sigma-Aldrich) in 0.1 M HCl
was prepared. The gold electrode was dipped in the solution, and the
potential was swept from 0 to 0.5 V versus a commercial Ag/AgCl
for two segments at a scan rate of 0.02 V s−1.
(v) GOx immobilization. 1 weight % (wt %) chitosan (product
#C3646, Sigma-Aldrich) solution was prepared by dissolving the chito-
san in 2 wt % acetic acid (product #695092, Sigma-Aldrich). The chito-
san solution was mixed with an exfoliated graphite (product #282863,
Sigma-Aldrich) solution (2 mg ml−1) in 1× phosphate-buffered saline
(Dulbecco’s PBS, WELGENE Inc.). The exfoliation process was con-
ducted using an ultrasonic machine (Sonics VCX-750, Vibra-Cell) for
30min. The chitosan/graphene solutionwasmixedwithGOx (0.05 gml−1;
product #G7141, Sigma-Aldrich) and bovine serum albumin (BSA)
(0.01 g ml−1; product #A2153, Sigma-Aldrich). A solution of GOx
(0.05 g ml−1) and BSA (0.01 g ml−1) was also prepared in 1× PBS.
GOx and BSA (0.8 ml) in a PBS solution was drop-casted on the porous
gold–deposited electrode. After drying the electrodes under ambient
conditions, 0.8 ml of GOx in the chitosan/graphene solution was
drop-casted on the electrode. After drying the electrodes under ambient
conditions, 2 ml of 0.5 wt % Nafion (product #309389, Sigma-Aldrich)Lee et al., Sci. Adv. 2017;3 : e1601314 8 March 2017was drop-casted on the glucose sensor. After drying of Nafion under am-
bient conditions, 0.8 ml of 2 wt % glutaraldehyde (product #G5882,
Sigma-Aldrich) was drop-casted on the glucose sensor for robust cross-
linking of the enzyme layer.
(vi) PANi electrodeposition. An aqueous solution of 0.1 M aniline
(product #242284, Sigma-Aldrich) in 1 MHCl was prepared. The gold
electrodewas dipped into the solution, and the potential was swept from
−0.2 to 1 V versus a commercial Ag/AgCl electrode for 60 segments at a
scan rate of 0.1 V s−1.
Fabrication of microneedles
A female PDMS (Sylgard 184, Dow Chemical) mold was prepared on
the basis of commercial microneedles (PAMAS, Prestige). The micro-
needles have a height of 1 mm and a round base diameter of 250 mm.
The drug-loaded PCNs [metformin (product #D150959, Sigma-Aldrich)
or chlorpropamide (product #C129531, Aladdin)] and a 2% hyaluronic
acid solution were drop-casted on the PDMS mold. The sample was
placed under vacuum until no bubble was generated. After degassing,
the sample was dried at room temperature. The microneedles were
carefully peeled from the mold. The PCM (tetradecanol; product
#185388, Sigma-Aldrich) was sprayed on the microneedles. The mor-
phology of the microneedles was examined with a field-emission SEM.
(For further details, see the Supplementary Materials.)SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/3/e1601314/DC1
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